Ozanimod - Celgene

Drug Profile

Ozanimod - Celgene

Alternative Names: Ozanimod-HCl; Ozanimod-hydrochloride; RPC-1063; RPC-1063-HCl

Latest Information Update: 10 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Scripps Research Institute
  • Developer Celgene Corporation; Receptos
  • Class Antiulcers; Indenes; Nitriles; Oxadiazoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Preregistration Multiple sclerosis
  • Phase III Crohn's disease; Ulcerative colitis

Most Recent Events

  • 11 Sep 2018 Celgene plans a phase I trial in volunteers in the US in September 2018 (NCT03665610)
  • 30 Jun 2018 Celgene initiates a phase I trial in Healthy volunteers in USA (NCT03694119)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top